Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) Operating Expenses (2018 - 2025)

Addex Therapeutics' Operating Expenses history spans 8 years, with the latest figure at $6.5 million for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 3.5% to $6.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.9 million, a 6.31% increase, with the full-year FY2025 number at $3.6 million, changed 0.28% from a year prior.
  • Operating Expenses came in at $6.5 million for Q4 2025, up from -$932300.4 in the prior quarter.
  • The five-year high for Operating Expenses was $35.4 million in Q4 2021, with the low at -$7.6 million in Q2 2022.
  • Historically, Operating Expenses has averaged $2.2 million across 5 years, with a median of -$1.0 million in 2023.
  • Peak annual rise in Operating Expenses hit 85.54% in 2023, while the deepest fall reached 75.13% in 2023.
  • Year by year, Operating Expenses stood at $35.4 million in 2021, then decreased by 12.46% to $31.0 million in 2022, then crashed by 75.13% to $7.7 million in 2023, then decreased by 12.86% to $6.7 million in 2024, then dropped by 3.5% to $6.5 million in 2025.
  • Business Quant data shows Operating Expenses for ADXN at $6.5 million in Q4 2025, -$932300.4 in Q3 2025, and -$929197.3 in Q2 2025.